【摘要】 目的:探讨S-1单药或联合方案治疗转移性肺癌的疗效和安全性。方法:36例转移性肺癌患者接受如下方案治疗:S-1单药组:S-1用量为40mg/m2,口服,bid,第1-14天,21天为一个周期。S-1联合多西他赛组(TS方案):S-1用量为40mg/m2,口服,bid,第1-14天,多西他赛75mg/m2,静脉滴注,第1天;21天为一个周期。结果:S-1单药组患者的ORR为14.3%,CBR为35.7%,而S-1联合多西他赛组ORR为22.7%,CBR为72.7%,两组ORR差异无统计学意义(P>0.05),CBR差异有统计学意义(P<0.05)。结论:S-1单药或者含S-1联合方案是转移性肺癌治疗的有效选择方案,患者不良反应可耐受。更多还原

【Abstract】 Objective:To evaluate the efficacy and toxicity of S-1 based chemotherapy in the treatment of metastatic lung cancer.Methods:Thirty-six patients with metastatic lung cancer were treated with S-1 based chemotherapy regimens.They were divided into 2 groups,group 1 was treated with S-1 40mg / m2orally twice daily on d 1-14,repeated every 3 weeks,group 2 was treated with S-1 as group 1,and combined with docetaxel 75mg/m2intravenous infusion on d 1,repeated every 3 weeks.The median treatment period of treatment was 3 cycles.Results:In group 1 the objective response rate(ORR) was 14.3% and clinical benefit rate(CBR) was 35.7%.In group 2 ORR was 22.7%,CBR was 72.7%.There was significantly difference in CBR between 2 groups(P < 0.05).Conclusion:S-1 based chemotherapy is effective and tolerable for metastatic lung cancer.更多还原